Facilitating Access to Approved Medication

Nivolumab Injection 100 mg
Nivolumab Injection is used to treat melanoma, lung cancer, kidney cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer, colon cancer, and liver cancer.

Get Access To Nivolumab Injection 100 mg

Nivolumab Injection was approved for medical use in the United States in 2021. It is on the World Health Organization’s List of Essential Medicines. It is available as a generic medication.
Nivolumab Injection Available Price In India UK Saudi Arabia

Nivolumab Injection

  • Generic Brand Available – On Request
  • API – Nivolumab Injection
  • Packaging – Glass Bottle
  • Strength – 40 mg, 100 mg

What is Nivolumab Injection used for?

Nivolumab Injection is given alone to treat melanoma, non-small cell lung cancer (NSCLC), Hodgkin lymphoma, head and neck cancer, urothelial cancer, advanced RCC, colorectal cancer, or esophageal cancer, it is usually given once every 2 or 4 weeks depending on your dosage for as long as your doctor recommends


    All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

    Get Access To Nivolumab Injection 100 mg

    Shreyaansh Lifesciences, Jaipur. India

    Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
    Branch Offices in India : Jaipur | New Delhi

    SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

    +91 99292 77766

    Facts of Medicines

    Nivolumab Injection 100 mg


    This Injection must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use the Ado-trastuzumab Emtansine Injectioninjection beyond the expiration date located on the carton and the vial.

    Nivolumab DOSAGE

    • Nivolumab is administered intravenously (IV) into the vein over 60 minutes every 2 weeks.
    • The amount of nivolumab that you will receive depends on many factors, your general health or other health problems, and the type of cancer or condition being treated. Higher doses do not give a better response and may cause increased toxicity. Your doctor will determine your dose and schedule.
    • If you miss any appointments call your healthcare provider as soon as possible to reschedule your appointment.

    Nivolumab SIDE EFFECTS

    • Most common adverse reactions include nausea, abdominal pain, headache, fatigue, vomiting, diarrhea, loss of appetite, and trouble sleeping.
    • More severe side effects of Nivolumab Injection include hypersensitivity, dark colored urine, yellowish of the skin, yellowish of the whites of the eyes, irregular heartbeat, stomach pain and unusual muscle pain. Symptoms of hypersensitivity include rash, fever/chills, depression, anxiety, and shortness of breath.


    • Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.
    • Nivolumab may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.
    • Patients with liver disease should be watchful and cautious in order to Nivolumab because it can aggravate the condition.
    • In patients with Nivolumab, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.
    • Nivolumab is not recommended for use in infants who are under 3 months of age.
    • Cases like lactic acidosis and severe hepatomegaly with steatosis occurred with the use of nucleoside analogues.
    • Sometimes serious hypersensitivity reactions have been associated with Nivolumab.

      FAQs – Medicine Questions

      Nivolumab Injection 100 mg
      Is nivolumab chemotherapy or immunotherapy?
      Nivolumab is a type of cancer treatment drug called an immunotherapy. It is a treatment for a number of different types of cancer. You might have it as part of a clinical trial for other types of cancer.
      How long do you stay on nivolumab?
      The average time for patients treated with ipilimumab/nivolumab to stay on therapy was about 2.5 months, but even among these patients, “two-thirds will stay in remission and do well,” he noted.
      What is nivolumab made from?
      Nivolumab is a genetically engineered anti-PD-1 mAb, developed by immunizing transgenic mice for human immunoglobulin loci with recombinant Chinese hamster ovary cells expressing human PD-1 and PD-1/human IgG1 Fc fusion protein 
      Where can I buy Nivolumab Injection?

      You can buy Nivolumab Injection Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

      The buyer should check the existing law in their home country before importing the product.

      What is the procedure to buy Nivolumab Injection?

      Patients can simply fill the order form or can send mail at info@treatmentoptions4u.com. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the Nivolumab Injection price as well as procurement procedure.

      Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.


      1. Bristol-Myers Squibb Pharmaceuticals Ltd., Electronic Medicines Compendium (EMC), [Revised on Jun 2021] [Accessed on 28th Jul 2021], https://www.medicines.org.uk/emc/files/pil.6888.pdf
      2. Bristol-Myers Squibb, [Revised on Jul 2021][Accessed on 28th Jul 2021], https://packageinserts.bms.com/pi/pi_opdivo.pdf
      3. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.